NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP
10x Genomics, Inc. TXG
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$642.8M
▲ 5.2% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-5.8%
Net margin · FY25
-6.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 642.8M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 7 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-5.8%
Return on equity, FY2025
ROE
Operating margin-9.5%
Net margin-6.8%
Return on assets-4.4%
Each USD of equity lost 6 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+16.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+7.6%
+16.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years+17.7%
Change, 10 years—
The share count grew 18% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.0B
total assets, end of FY2025
Total assetsUSD 1.0B
EquityUSD 796.3M
CashUSD 474.0M
Current ratio4.46×
Equity funds 76% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.6
0.6
0.6
0.5
0.5
0.3
0.2
0.1
0.1
Operating income $B
−0.1
−0.2
−0.3
−0.2
−0.1
−0.5
−0.0
−0.1
−0.0
EBITDA $B
−0.0
−0.2
−0.2
−0.1
−0.0
−0.5
−0.0
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.2
−0.3
−0.2
−0.1
−0.5
−0.0
−0.1
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−5.8
−25.2
−33.0
−20.5
−7.5
−93.6
−31.2
·
·
Shares out B
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed